DXCM Quote, Financials, Valuation and Earnings

Insulet has a net margin of 13.54% compared to DexCom's net margin of 14.25%. DexCom's return on equity of 30.96% beat Insulet's return on equity of 49.55%.

DexCom has a consensus price target of $96.26, signalling upside risk potential of 20.27%. On the other hand Insulet has an analysts' consensus of $285.63 which suggests that it could grow by 7.16%. Given that DexCom has higher upside potential than Insulet, analysts believe DexCom is more attractive than Insulet.

DexCom has a beta of 1.125, which suggesting that the stock is 12.541% more volatile than S&P 500. In comparison Insulet has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.859%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than Insulet quarterly revenues of $543.9M. DexCom's net income of $134.6M is higher than Insulet's net income of $77.5M. Notably, DexCom's price-to-earnings ratio is 47.93x while Insulet's PE ratio is 45.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.40x versus 10.27x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

QuidelOrtho has a net margin of 13.54% compared to DexCom's net margin of -2.74%. DexCom's return on equity of 30.96% beat QuidelOrtho's return on equity of -47.52%.

DexCom has a consensus price target of $96.26, signalling upside risk potential of 20.27%. On the other hand QuidelOrtho has an analysts' consensus of -- which suggests that it could grow by 13.98%. Given that DexCom has higher upside potential than QuidelOrtho, analysts believe DexCom is more attractive than QuidelOrtho.

DexCom has a beta of 1.125, which suggesting that the stock is 12.541% more volatile than S&P 500. In comparison QuidelOrtho has a beta of 0.107, suggesting its less volatile than the S&P 500 by 89.318%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. QuidelOrtho offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. QuidelOrtho pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than QuidelOrtho quarterly revenues of $727.1M. DexCom's net income of $134.6M is higher than QuidelOrtho's net income of -$19.9M. Notably, DexCom's price-to-earnings ratio is 47.93x while QuidelOrtho's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.40x versus 1.07x for QuidelOrtho. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 13.54% compared to DexCom's net margin of -9.53%. DexCom's return on equity of 30.96% beat Tandem Diabetes Care's return on equity of -47.23%.

DexCom has a consensus price target of $96.26, signalling upside risk potential of 20.27%. On the other hand Tandem Diabetes Care has an analysts' consensus of -- which suggests that it could grow by 41.82%. Given that Tandem Diabetes Care has higher upside potential than DexCom, analysts believe Tandem Diabetes Care is more attractive than DexCom.

DexCom has a beta of 1.125, which suggesting that the stock is 12.541% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.425%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than Tandem Diabetes Care quarterly revenues of $244M. DexCom's net income of $134.6M is higher than Tandem Diabetes Care's net income of -$23.3M. Notably, DexCom's price-to-earnings ratio is 47.93x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.40x versus 2.75x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of 13.54% compared to DexCom's net margin of -51.95%. DexCom's return on equity of 30.96% beat Dentsply Sirona's return on equity of -13.34%.

DexCom has a consensus price target of $96.26, signalling upside risk potential of 20.27%. On the other hand Dentsply Sirona has an analysts' consensus of $22.96 which suggests that it could grow by 22.87%. Given that Dentsply Sirona has higher upside potential than DexCom, analysts believe Dentsply Sirona is more attractive than DexCom.

DexCom has a beta of 1.125, which suggesting that the stock is 12.541% more volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.545%.

DexCom has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 3.32% to investors and pays a quarterly dividend of $0.16 per share. DexCom pays -- of its earnings as a dividend. Dentsply Sirona pays out -87.88% of its earnings as a dividend.

DexCom quarterly revenues are $994.2M, which are larger than Dentsply Sirona quarterly revenues of $951M. DexCom's net income of $134.6M is higher than Dentsply Sirona's net income of -$494M. Notably, DexCom's price-to-earnings ratio is 47.93x while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom is 8.40x versus 0.99x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.